Key result
Combination therapy with an ARB and simvastatin did not significantly reduce the incidence of major adverse cardiac events at 1 year compared to an ACE inhibitor and simvastatin in patients with acute coronary syndrome after percutaneous coronary intervention.
Why the study?
Does combination therapy with an ARB and simvastatin improve clinical outcomes compared to an ACE inhibitor and simvastatin in patients with acute coronary syndrome who underwent PCI?
Population
396 patients with acute coronary syndrome who underwent percutaneous coronary intervention between June 2002…
Comparison
Angiotensin II type 1 receptor blocker and… vs Angiotensin converting enzyme inhibitor and…
Design
Cohort
Follow-up
1 year (clinical), 6 months (angiographic)
Authors
Loading...
No superiority of ARB-simvastatin seen in this cohort; leaves open whether RCTs would favor one regimen in ACS post-PCI.
Cohort (n=396)
No
Does combination therapy with an ARB and simvastatin improve clinical outcomes compared to an ACE inhibitor and simvastatin in patients with acute coronary syndrome who underwent PCI?
Absolute Event Rate: 19% vs 21%
p-value: p=0.565
Combination therapy with an ARB and simvastatin does not provide superior clinical or angiographic benefits compared to an ACE inhibitor and simvastatin in ACS patients post-PCI.
Hong et al. (2005) conducted a cohort in Acute coronary syndrome after percutaneous coronary intervention (n=396). Angiotensin II type 1 receptor blocker (ARB) and simvastatin vs. Angiotensin converting enzyme (ACE) inhibitor and simvastatin was evaluated on Major adverse cardiac events (MACE) at 1 year (p=0.565). Combination therapy with an ARB and simvastatin did not significantly reduce the incidence of major adverse cardiac events at 1 year compared to an ACE inhibitor and simvastatin in patients with acute coronary syndrome after percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: